Report: U.S. Weighs Letting Some Peptides Be Sold for Now

Big peptide news broke this week. On October 7, The Washington Post reported that the Trump administration is drafting a plan to let some unapproved peptides be sold for a while.

The report cites two unnamed people familiar with the plan. Nothing has been announced yet. Still, for peptide fans, it is a big sign that access could open up.

What happened

A peptide is a short chain of amino acids. Think of a short bead bracelet. New here? Start with what a peptide is.

According to the Post, the plan would let some compounding pharmacies make certain peptides. A compounding pharmacy mixes a medicine for one patient. It is a bit like a bakery that makes cakes to order.

The key word is "temporary." The sales would be a stopgap, like a bridge. It would last while health officials write new rules. Officials also want guardrails, or safety rails, the sources said.

Some big things are still unknown:

• Which peptides it would cover.
• When it might start.
• Whether it will change first.

The health department, HHS, did not comment to the Post.

In April 2026, the FDA took BPC-157 and other peptides off its safety-risk list for compounding. In July, an FDA advisory panel backed six of seven peptides, including KPV.

An advisory panel is a group of outside experts. Its vote is advice, not a final decision.

Why it matters

Peptides are getting more popular fast, the Post reported. Wellness fans, fitness buffs and celebrities talk about them. They are popular with supporters of the Make America Healthy Again, or MAHA, movement, too. Health Secretary Robert F. Kennedy Jr. has called himself a "big fan."

Today, many peptides are sold in gray and black markets, the Post reported. Some are even made in homes.

A trade group for compounding pharmacies told the Post that pharmacies would be a better option. It has asked the FDA for "enforcement discretion." It means the FDA agrees, for a time, not to act against pharmacies making these peptides.

The group also wants clear patient info, reports of serious side effects, and data collection. That data could teach scientists a lot.

Not everyone agrees. FDA scientists said there was not enough proof of safety or how well they work. Some experts worry wider access adds risk. One said guardrails could help spot problems.

For now, none of these peptides is FDA-approved.

What happens next

A lasting change would go through the bulks list. Think of it as the FDA's ingredient shelf. It lists the raw ingredients compounding pharmacies may use.

To add the panel's peptides, the FDA plans to publish a proposed rule first. Then the public can comment. The Post said it is unclear when that rule will come.

A temporary plan could move faster than that. But until officials announce it, the reported plan is not in effect.

More is coming. The same panel is expected to review five more peptides in February 2027.

The bottom line

• The Washington Post reports a plan to let some unapproved peptides be sold for a while.
• The plan is not announced, and which peptides it covers is unknown.
• A lasting change still needs an FDA rule with public comment.